Amorphical Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.amorphical.com
Clinical Trials
9
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:6
Phase 2:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (66.7%)Not Applicable
2 (22.2%)Phase 2
1 (11.1%)Evaluating the Safety and Efficacy of AMOR-1 As a Treatment for Hypocalcemia Associated with Hypoparathyroidism in Adults
Phase 2
Recruiting
- Conditions
- Hypoparathyroidism
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Amorphical Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT06547151
- Locations
- 🇮🇱
Hadassah Ein Kerem Medical Center, Jerusalem, Israel
🇮🇱Barzilai Medical Center, Ashkelon, Israel
🇮🇱Soroka Medical Center, Beer Sheva, Israel
A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism
Not Applicable
Terminated
- Conditions
- Hypoparathyroidism
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Amorphical Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06288490
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.
Phase 1
Completed
- Conditions
- Covid19
- Interventions
- Drug: AMOR 18 Powder & InhalationDrug: Placebo
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Amorphical Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04900337
- Locations
- 🇮🇱
Shamir MC, Be'er Ya'aqov, Israel
🇮🇱Tel-Aviv Sourasky MC, Tel Aviv, Israel
🇮🇱Ziv MC, Tsefat, Israel
The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects
Phase 1
Terminated
- Conditions
- Oncology
- Interventions
- Drug: Amorphous Calcium Carbonate (ACC) - Amor
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Amorphical Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT03582280
- Locations
- 🇮🇱
Hadassah Ein Carem, Jerusalem, Israel
Improving Function,Welfare of Late-stage Cancer Subjects by ACC
Phase 1
Terminated
- Conditions
- Solid Malignancies, With or Without Lung Metastases
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Amorphical Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03057314
- Locations
- 🇮🇱
Meir, Kfar Saba, Israel
- Prev
- 1
- 2
- Next
News
No news found